Fradet, Vincent <br/><br/>
Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.  [electronic resource] 

 -  BJU international  03 2018 
 - 399-404 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1464-410X 
<br/><br/><label>Standard No.: </label>10.1111/bju.14041  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>5-alpha Reductase Inhibitors--therapeutic use<br/>Aged<br/>Antigens, Neoplasm--urine<br/>Dutasteride--therapeutic use<br/>Finasteride--therapeutic use<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Grading<br/>Prospective Studies<br/>Prostatic Neoplasms--pathology<br/>Risk Factors<br/>Single-Blind Method<br/>Watchful Waiting--methods